What TKMR has is the first round of second-generation cyclophilin inhibitors -NVP018 which
have the potential for therapeutic application in a number of
areas, in particular chronic viral infection. NVPO18 has a high po-
tency, a high barrier to resistance and shows activity on multiple steps of the
viral life cycle- plus it hs oral bioavailability. I have noted
recent publications suggesting that NVPO18 might
also have additional impact on interferon regulatory factors,
which have long been implicated in the escape of certain viruses,
such as HCV and HIV, from the immune system.
While cyclophilin inhibitors like NVPO18 do not
exhibit inhibition of all viruses, these "natural products" have been shown to have
activity against a wide variety of both RNA viruses including corona-
viruses, HIV, and HCV). Also against various DNA viruses like human CMV, HBV and varicella zoster virus.
TKMR has an agent that may lead to a big step forward in the treatment of viral illnesses.
As a psychiatrist I am waiting for this medication - many recent advances in understanding the role of serotonin have led to more rational drug design approaches to psychosis in PD- these are able to deliver a novel pharmacological treatment with recently proven efficacy in clinical trials of people with PD and psychosis. Pimavanserin represents an important addition to treatment